As more research emerges surrounding the standardization of tumor mutational burden (TMB) assessment, a universal definition of “high TMB” across cancer types does not appear to be feasible.

Meet us in D.C. at Immunology 2017 on May 12–16!

Drop by and meet our scientists at QIAGEN booth #132 to get insights into advanced bioinformatics solutions. Dr. Jean-Noel Billaud will present a poster on the application of Ingenuity Pathway Analysis (IPA) on endometrioid endometrial carcinoma metastatic progression analysis.
Poster topic: Identification of potential immune targets in controlling endometrioid endometrial carcinoma metastatic progression

Author: Jean-Noel Billaud, Ph.D., Senior Principal Scientist – QIAGEN Bioinformatics

Topic category: Tumor Immunology

Date: Sunday, May 14

Time: 2.30 p.m. – 5.00 p.m.

In addition to our advanced bioinformatics solutions, QIAGEN also provides a broad range of assay technologies for immunological research, enabling analysis of gene expression and regulation, epigenetic modification, genotyping, and signal transduction pathway activation. Visit QIAGEN’s immunology research portal here.

We look forward to seeing you at Immunology 2017 in D.C. on May 12–16!